NHP Intracerebroventricular (ICV) Injection | Prisys Biotech
Intracerebroventricular (ICV) administration is a direct central nervous system (CNS) delivery approach in which therapeutic agents are administered into the brain ventricular system. By bypassing the blood–brain barrier (BBB), ICV injection enables widespread distribution of therapeutics through cerebrospinal fluid (CSF) circulation, supporting broad CNS exposure and enhanced target engagement.
Prisys Biotech provides specialized ICV dosing, ventricular catheterization, and CNS delivery support services in non-human primate (NHP) models, helping clients advance gene therapies, biologics, oligonucleotides, enzyme replacement therapies, and other CNS-targeted therapeutics.
Service Overview
Prisys offers integrated ICV administration services designed for:
- Direct CNS drug delivery via ventricular access
- Acute and repeat-dose ICV administration studies
- CSF sampling and pharmacokinetic evaluation
- Implantable reservoir and catheter systems
- CNS safety and neurohistopathology assessment
- MRI-guided stereotaxic neurosurgical support
These capabilities support translational studies ranging from early feasibility evaluation to non-GLP and GLP-enabling CNS programs.
Key Technical Capabilities
MRI-Guided Stereotaxic Targeting
Accurate ventricular access is critical for successful ICV studies. Prisys combines Intraprocedural MRI-guided drug delivery system to achieve precise targeting of lateral or third ventricles with high reproducibility.
Using image-guided planning and experienced neurosurgical teams, the platform supports:
- Precise cannula placement
- Controlled infusion depth and trajectory
- Verification of ventricular access
- Reduced procedural variability
This approach is particularly important in NHP studies, where anatomical complexity requires clinically relevant precision.
Controlled CNS Infusion
ICV administration requires carefully controlled infusion parameters to ensure consistent CNS distribution while minimizing tissue disruption or intracranial pressure fluctuations.
Prisys supports:
- Bolus and slow infusion paradigms
- Micro-infusion protocols
- Longitudinal repeat-dosing studies
- Integration with Convection-Enhanced Delivery (CED) strategies where appropriate
These capabilities are optimized for CNS therapeutics requiring broad CSF-mediated exposure.
Reservoir and Catheter Implantation
For chronic or repeat-dose studies, Prisys provides implantable ventricular access systems, including Ommaya-type reservoir approaches.
These systems enable:
- Repeat ICV dosing without repeated stereotaxic puncture
- Serial CSF sampling
- Long-term CNS exposure studies
- Reduced procedural burden during chronic studies
The platform is particularly valuable for enzyme replacement therapies, antisense oligonucleotides, and viral vector programs.
Integrated CNS Safety Evaluation
ICV administration studies may involve procedure-related and CNS-specific risks that require comprehensive evaluation. Prisys provides integrated assessment capabilities including:
- Neurological and clinical monitoring
- Behavioral assessment using AI-based NHP Behavior Analysis System
- MRI/PET imaging support
- Neurohistopathology evaluation
- Assessment of inflammation, gliosis, hemorrhage, and ventricular changes
Translational Applications
ICV administration is widely used in preclinical CNS research for therapeutics requiring broad distribution throughout the ventricular and CSF systems.
Typical applications include:
- Gene therapy and AAV vector delivery
- Enzyme replacement therapies (ERT)
- Antisense oligonucleotides (ASOs)
- Neurodegenerative disease research
- Lysosomal storage disorders
- Pediatric and rare CNS disease programs
Compared with localized Intracerebral (ICM) injection delivery and NHP Intrathecal (IT) Dosing, ICV administration may provide broader CNS exposure across the brain and spinal cord, making it suitable for diffuse neurological diseases.
Advanced CNS Delivery Infrastructure at Prisys
Prisys has established an advanced translational CNS research platform integrating:
- MRI-compatible stereotaxic systems
- Clinical-grade surgical suites
- Image-guided drug delivery technologies
- NHP behavioral analysis capabilities
- Clinical imaging modalities including MRI, CT, and PET
This integrated infrastructure supports highly specialized CNS delivery studies with strong translational relevance from preclinical development toward clinical application.
FAQ
Q: What is the main advantage of ICV administration?
A: ICV administration bypasses the blood–brain barrier and enables therapeutics to distribute broadly through the cerebrospinal fluid, supporting widespread CNS exposure.
Q: When is ICV preferred over IT or ICM administration?
A: ICV is often preferred when broad ventricular or CNS distribution is required, particularly for diffuse neurological diseases or therapies intended to circulate extensively through the CSF system.
Q: Can Prisys support chronic or repeat-dose ICV studies?
A: Yes. Prisys supports long-term ventricular catheterization and reservoir implantation strategies for repeat dosing, serial CSF sampling, and chronic CNS exposure studies.
Hot Tags: nhp intracerebroventricular (icv) injection | prisys biotech, research, study, monkey, gene therapy, pk and pd, PK PD ADME, adme of drug, preclinical pk pd, Pharmacodynamics, adme pharmacodynamics
Previous
Nose-to-Brain Drug DeliveryYou Might Also Like
Send Inquiry